<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>The New England Journal of Medicine: Search Results in Allergy/Immunology</title>
        <description>The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Allergy/Immunology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.</description>
        <link>https://www.nejm.org/action/showPodcastsFeeds</link>
        <generator>NEJM Group</generator>
        <lastBuildDate>Fri, 20 Nov 2026 17:55:05 GMT</lastBuildDate>
        <copyright>2026 NEJM Group</copyright>
        <language>en-us</language>
        <ttl>1440</ttl>
        <atom:link href="https://onesearch-rss.nejmgroup-production.org/specialty/allergy-immunology" rel="self" type="application/rss+xml"/>
        <item>
            <title>Acute Respiratory Distress Syndrome</title>
            <description>ARDS is marked by noncardiogenic pulmonary edema and hypoxemia. Management includes treatment of the underlying cause and avoidance of ventilator-induced lung injury and fluid overload. Prone positioning and ECMO can also be useful.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMra2601172?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMra2601172</guid>
            <dc:creator>Carolyn S. Calfee, Daniel F. McAuley</dc:creator>
            <dc:date>2026-11-19</dc:date>
            <dc:title>Acute Respiratory Distress Syndrome</dc:title>
        </item>
        <item>
            <title>Double Take: Closing the Gap</title>
            <description>This Double Take video reviews the differential diagnosis for a woman with fever and recurrent sinonasal symptoms and how it evolves as new clinical findings are presented.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMp2516854?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMp2516854</guid>
            <dc:creator>Lakshmi Ravindra, Kimberly Knoper, Nadine Tan, Caren G. Solomon</dc:creator>
            <dc:date>2026-11-19</dc:date>
            <dc:title>Double Take: Closing the Gap</dc:title>
        </item>
        <item>
            <title>Revertant Autograft Replacement in Recessive Dystrophic Epidermolysis Bullosa</title>
            <description>Two adolescents with epidermolysis bullosa received autografts from revertant skin, which provided durable epidermal replacement over approximately 95% of the body-surface area in one patient and 50% in the other.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMc2517823?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMc2517823</guid>
            <dc:creator>Akiharu Kubo, Hisato Suzuki, Noriko Ono, Sonoko Saito, Satomi Aoki, Yuki Ogawa, Hiroto Horikawa, Yoshio Nakamura, Takeru Funakoshi, Tomoyo Tanaka, Masukazu Inoie, Kenjiro Kosaki, Masayuki Amagai</dc:creator>
            <dc:date>2026-11-19</dc:date>
            <dc:title>Revertant Autograft Replacement in Recessive Dystrophic Epidermolysis Bullosa</dc:title>
        </item>
        <item>
            <title>Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial</title>
            <description>An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2607544?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2607544</guid>
            <dc:creator>Jonathan Barratt, Youssef M.K. Farag, Kara Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette Bruchfeld, Hiddo J.L. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Ángel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo-Infante, Stephen L. Lake, Ajay K. Singh, Stephen Nolan, Richard A. Lafayette, the I CAN Trial Group*</dc:creator>
            <dc:date>2026-11-12</dc:date>
            <dc:title>Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial</dc:title>
        </item>
        <item>
            <title>Interferon-γ Underlying Thymoma-Associated Immune Dysregulation</title>
            <description>In an observational study, thymoma-associated immune dysregulation was characterized by interferon-γ pathway activation. Four patients with severe disease treated with Janus kinase 1/2 inhibitors had clinical and biomarker responses.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMc2607434?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMc2607434</guid>
            <dc:creator>Iivo Hetemäki, Chen Wang, Rachel Wu, Joseph Pechacek, Taura Webb, Deanna Riley, Lucas dos Santos Dias, Heather Moorman, Princess Barber, Lindsey B. Rosen, Annalie Harris, Sebastian Ochoa, Karthik Darma, Maria Semenova, Laercio Lopez Da Silva, Kai Kisand, Tovah E. Markowitz, Peter D. Burbelo, Monika Fischer, Mark Raffeld, Tyler Hulett, Jennifer Stoddard, Sergio D. Rosenzweig, Christopher G. Kanakry, Kathy L. McGraw, Joseph Rocco, Luigi D. Notarangelo, Christa S. Zerbe, Ivan Fuss, Anjali Rai, Theo Heller, Patrick J. Loehrer, Eliisa Kekäläinen, Alexandra F. Freeman, Arun Rajan, Timi Martelius, Katherine R. Calvo, Steven M. Holland, Roderick Marion, Stefania Pittaluga, Michail S. Lionakis</dc:creator>
            <dc:date>2026-11-12</dc:date>
            <dc:title>Interferon-γ Underlying Thymoma-Associated Immune Dysregulation</dc:title>
        </item>
        <item>
            <title>Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity</title>
            <description>The WOMAC pain score and body weight decreased significantly more with retatrutide than with placebo in patients with painful knee osteoarthritis and obesity.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2610676?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2610676</guid>
            <dc:creator>Thomas J. Schnitzer, David J. Hunter, Philip G. Conaghan, Arya M. Sharma, Sue D. Pedersen, Kaiyi Chen, So Young Park, Nune Makarova, Kathryn Giblin, Tammy Forrester, the TRIUMPH-4 and TRIUMPH-1-OA Investigators*</dc:creator>
            <dc:date>2026-11-08</dc:date>
            <dc:title>Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity</dc:title>
        </item>
        <item>
            <title>Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity</title>
            <description>In this trial involving participants with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2604169?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2604169</guid>
            <dc:creator>Ania M. Jastreboff, Lee M. Kaplan, Melanie J. Davies, John P.H. Wilding, Nadia N. Ahmad, Megan Murray, Yu Du, Nune Makarova, Kathryn Giblin, Nanette C. Schloot, Yan Wang, the TRIUMPH-1 Investigators*</dc:creator>
            <dc:date>2026-11-05</dc:date>
            <dc:title>Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity</dc:title>
        </item>
        <item>
            <title>Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy</title>
            <description>Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608682?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608682</guid>
            <dc:creator>Jonathan Barratt, Hong Zhang, Seung Hyeok Han, Yuzuke Suzuki, James Tumlin, Bobby Chacko, Irene L. Noronha, Arvind Madan, Raphaël Duivenvoorden, Jamil R. Azzi, Carla Nester, Cassie Dong, Neil Ahluwalia, Jiahua Li, Carmen Bozic, Ogo Egbuna, Muh Geot Wong, Richard Lafayette, the RAINIER AIS-D08 Trial Group*</dc:creator>
            <dc:date>2026-11-05</dc:date>
            <dc:title>Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy</dc:title>
        </item>
        <item>
            <title>A Triple Incretin Agonist for Obesity, Osteoarthritis, and Sleep Apnea</title>
            <description>Obesity is the most common chronic disease in the world.1 Even more devastating are its sequelae, which range from sleep apnea and osteoarthritis to an increased risk of cardiovascular disorders, renal disease, and cancer. In the past 15 years, the use of glucagon-like peptide 1 (GLP-1) receptor agonists...</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMe2613108?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMe2613108</guid>
            <dc:creator>Clifford J. Rosen, Julie R. Ingelfinger</dc:creator>
            <dc:date>2026-11-05</dc:date>
            <dc:title>A Triple Incretin Agonist for Obesity, Osteoarthritis, and Sleep Apnea</dc:title>
        </item>
        <item>
            <title>Tozorakimab to Prevent COPD Exacerbations</title>
            <description>In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2606998?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2606998</guid>
            <dc:creator>Frank C. Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens, Fernando J. Martinez, Jinping Zheng, Maarten van den Berge, Matteo Bonini, MeiLan K. Han, Dave Singh, Gerard J. Criner, Christopher E. Brightling, Alberto Papi, Surya P. Bhatt, Martin Jenkins, Marta Mikosz, Piotr Chołbiński, Monika Ziemiecka, Magnus Löfdahl, Deepa Arya, Madhavi Yadavalli, Bryan H. Brodek, Malin Fagerås, Samuel Bardsley, Neil Martin, Rajesh Patel, Ioannis Psallidas, the OBERON and TITANIA Trial Investigators*</dc:creator>
            <dc:date>2026-10-29</dc:date>
            <dc:title>Tozorakimab to Prevent COPD Exacerbations</dc:title>
        </item>
        <item>
            <title>Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis</title>
            <description>In this phase 3, double-blind, randomized trial involving patients with IgA nephropathy, sibeprenlimab stabilized the eGFR slope over 24 months, consistent with a reduced risk of kidney-function decline.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2609127?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2609127</guid>
            <dc:creator>Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard Lafayette, Vladimír Tesař, Hernán Trimarchi, Kevin Carroll, Ian S.D. Roberts, Vivekanand Jha, Alejandra Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, Jin-Bor Chen, José Suassuna, Jing Xia, Lokesh Shah, Vlado Perkovic, the VISIONARY Trial Investigators Group*</dc:creator>
            <dc:date>2026-10-22</dc:date>
            <dc:title>Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis</dc:title>
        </item>
        <item>
            <title>Ianalumab for the Treatment of Patients with Sjögren’s Disease</title>
            <description>In two trials involving patients with active Sjögren’s disease, decreases in disease activity at 48 weeks were greater with monthly ianalumab than with placebo, but differences in response rates and symptom scores were not significant.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2601088?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2601088</guid>
            <dc:creator>Xavier Mariette, Thomas Grader-Beck, Stephanie Finzel, Elena Schiopu, Athena Papas, Valerie Devauchelle-Pensec, Monika Sopala, Xiaofeng Zeng, Ghaith Noaiseh, Tsutomu Takeuchi, Uma Kumar, Josef Hermann, Hiroki Ozawa, Robert Fox, Susan Zong, Deepak Narayanswamy, Xiaomei Li, Wen-Lin Luo, Janice Woznicki, Laurie Debonnett, Xuan Zhu, Linchen He, Franziska Matzkies, Angelika Jahreis, Devendra Kumar Jain, Brian Porter, Carol Lau, Thomas Dörner, Sara S. McCoy, Simon J. Bowman, Wolfgang Hueber, the NEPTUNUS-1 and NEPTUNUS-2 Investigators*</dc:creator>
            <dc:date>2026-10-22</dc:date>
            <dc:title>Ianalumab for the Treatment of Patients with Sjögren’s Disease</dc:title>
        </item>
        <item>
            <title>Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis</title>
            <description>In patients with IgA nephropathy, atacicept, a human TACI–Fc fusion protein that modulates B-cell activity, slowed and stabilized the decline in the eGFR as compared with placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2610103?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2610103</guid>
            <dc:creator>Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K.S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimír Tesař, Hernán Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard Lafayette, the ORIGIN Phase 3 Trial Investigators*</dc:creator>
            <dc:date>2026-10-22</dc:date>
            <dc:title>Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis</dc:title>
        </item>
        <item>
            <title>Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead</title>
            <description>The discovery of H. pylori has advanced the prevention and treatment of gastritis, peptic ulcers, and gastric cancer. Progress has been made in the research of H. pylori infection. These advances are discussed in this review.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMra2414530?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMra2414530</guid>
            <dc:creator>Hong Li, Francis Megraud, Barry J. Marshall</dc:creator>
            <dc:date>2026-10-22</dc:date>
            <dc:title>Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead</dc:title>
        </item>
        <item>
            <title>Ianalumab in Sjögren’s Disease — A First Step</title>
            <description>Sjögren’s disease has long frustrated clinicians, trialists, and — most important — patients for whom effective treatments remain elusive. Glandular dysfunction causes dryness; fatigue and pain add substantially to daily burden; and systemic manifestations can affect major organs. These dimensions of disease do not necessarily track together. Management of dryness...</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMe2610330?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMe2610330</guid>
            <dc:creator>Simone Negrini</dc:creator>
            <dc:date>2026-10-22</dc:date>
            <dc:title>Ianalumab in Sjögren’s Disease — A First Step</dc:title>
        </item>
        <item>
            <title>Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis</title>
            <description>In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2604435?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2604435</guid>
            <dc:creator>Maria T. Abreu, Britta Siegmund, Lindsey Surace, Ngozi Erondu, Minhu Chen, Karen Chachu, Edouard Louis, Katsuyoshi Matsuoka, Jimmy Limdi, Edmund Arthur, Nicole Houck, Colleen Marano, Marion L. Vetter, Bin Zou, Joyce Zhan, Mary Ellen Frustaci, Arun K. Kannan, Grazyna Rydzewska, Edward V. Loftus Jr., Vipul Jairath, the ANTHEM-UC Study Group*</dc:creator>
            <dc:date>2026-10-15</dc:date>
            <dc:title>Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis</dc:title>
        </item>
        <item>
            <title>Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema</title>
            <description>In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2600931?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2600931</guid>
            <dc:creator>Danny M. Cohn, Padmalal Gurugama, Hilary J. Longhurst, Emel Aygören-Pürsün, Timothy J. Craig, Henriette Farkas, Joshua Jacobs, William R. Lumry, Markus Magerl, Jonny Peter, Marc A. Riedl, David Maag, Adele Golden, Mrinal Y. Shah, Andrea Sutherland, Catherine R. Miller, Ahmed M. Abdelhady, Yuanxin Xu, James S. Butler, David Lebwohl, John Leonard, Aleena Banerji, the HAELO Investigators*</dc:creator>
            <dc:date>2026-10-15</dc:date>
            <dc:title>Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema</dc:title>
        </item>
        <item>
            <title>Adapting to Genomic Medicine</title>
            <description>Hereditary angioedema is a disorder characterized by unpredictable, transient episodes of swelling and pain of various body parts. It can be life-threatening if the airway is involved. Current therapies include several different products that are administered prophylactically or at the onset of symptoms, and the prophylactic products must be administered...</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMe2608188?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMe2608188</guid>
            <dc:creator>Peter Marks</dc:creator>
            <dc:date>2026-10-15</dc:date>
            <dc:title>Adapting to Genomic Medicine</dc:title>
        </item>
        <item>
            <title>Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia</title>
            <description>A 19-year-old woman presented with fever and cervical lymphadenopathy. The white-cell count was 2900 per microliter (reference range, 4000 to 11,000), and the lactate dehydrogenase level was elevated. A diagnosis was made.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMcpc2603182?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMcpc2603182</guid>
            <dc:creator>Ezra M. Cohen, Shohei Fujita, Daniel R. Brown, Vanda F. Torous</dc:creator>
            <dc:date>2026-10-08</dc:date>
            <dc:title>Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia</dc:title>
        </item>
        <item>
            <title>Obexelimab for the Treatment of IgG4-Related Disease</title>
            <description>In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2601337?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2601337</guid>
            <dc:creator>Emanuel Della-Torre, Matthew C. Baker, Wen Zhang, Cory A. Perugino, Guy Katz, Yoshiya Tanaka, Arezou Khosroshahi, Alexander Kleger, Nicolas Schleinitz, Fernando Martinez-Valle, Hendrik Schulze-Koops, Shingo Nakayamada, Vinciane Rebours, Kazuichi Okazaki, Lingli Dong, Mollie Carruthers, Luke Y.C. Chen, Luca Frulloni, Alireza Meysami, Hiroki Takahashi, Mitsuhiro Kawano, Yanying Liu, Takako Saeki, Mikael Ebbo, Tobias Alexander, Andrés González García, Omer Karadag, Maria Maślińska, Shauna M. Quinn, Allen Poma, Audrey Wells, Thomas J. Greene, John H. Stone, Emma L. Culver, the INDIGO Trial Investigators*</dc:creator>
            <dc:date>2026-10-01</dc:date>
            <dc:title>Obexelimab for the Treatment of IgG4-Related Disease</dc:title>
        </item>
    </channel>
</rss>